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Topical Imiquimod Treatment Prevents UV-Light
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Immune Tolerance
Thomas H. Thatcher1, Irina Luzina2, Rita Fishelevich3, Mark A. Tomai4, Richard L. Miller4 and
Anthony A. Gaspari3
Imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine) is a TLR7 agonist that induces cytokine
production in TLR7 bearing antigen-presenting cells (APCs), including IL-12, a cytokine that has been
demonstrated to be a critical effector molecule for contact hypersensitivity (CHS). To test our hypothesis that
topical applications of imiquimod may protect the skin immune system against the deleterious effects of UV
light exposures, we treated animals with this agent, or its vehicle or nothing before UV exposures. Although
topical imiquimod exposures before UV light did not prevent the depletion of epidermal Langerhans cells, it
did prevent the loss of CHS. IL-12 was important in the protective role of imiquimod in preventing UV-induced
loss of CHS, as systemic treatment of mice with an anti-IL-12 p70 monoclonal antibody blocked the protective
effects of imiquimod. Additionally, only imiquimod-treated mice were resistant to hapten-specific tolerance
induction after UV irradiation at the site of the initial sensitization with the hapten 2,4 dinitro-1-fluorobenzene.
To model for the effects of TLR7 activation on the UV effect on antigen-APCs, XS52 cell line was used to study
this interaction in an in vitro model system. This cell line expressed mRNA for TLR7, downregulated IkB,
phosphorylated c-Jun N-terminal kinase, and secreted cytokines after exposure to imiquimod or lipopoly-
saccharide. Activation of the TLR7 signaling pathway on XS52 before UV-light exposures enhanced IL-12p70
secretion by this cell line. Similarly, activation of TLR7 on XS52 before UV-light exposure also prevented the
UV-induced loss of IFN-g triggering in T cells during an allogeneic mixed lymphocyte reaction. Imiquimod-
treated, UV-irradiated XS52 triggered a more vigorous IFN-g production than did either imiquimod-treated XS52
or UV-irradiated XS52, again suggesting a synergy between the two treatments. Lastly, enriched lymph node
CD11cþ APCs from mice treated with UV irradiation, imiquimod alone or the combination of UV irradiation
and imiquimod indicated the same in vivo synergy between imiquimod irradiation and UV irradiation in
enhancing IL-12p70 production. These data suggest that topical imiquimod applications may play a role in
preventing UV-induced impairment of the skin immune system, which is thought to be one of the critical events
that allow the development of UV-induced skin cancers.
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INTRODUCTION
UV light has a variety of acute and chronic deleterious effects
on mammalian skin, which are thought to be important in the
development of skin cancer. One of the acute effects of UV-
light exposure is its adverse effects on contact hypersensitivity
(CHS), which is dependent on interactions between epider-
mal Langerhans cells (LCs) and skin-associated lymphoid
tissue. UV light is known to physically deplete LCs from the
epidermis (Toews et al., 1980; Aberer et al., 1981), which is
thought to be an important mechanism of UV suppression of
CHS. Those LCs that survive UV exposure are impaired in the
ability to mature, and hence to present haptens to Th1-
lymphocytes. The result of this impaired maturation and
ability to activate Th1-lymphocytes is clonal anergy in
T-lymphocytes that would normally develop into
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hapten-specific Th- and Tc-lymphocytes that would normally
be effector cells for CHS (Cruz et al., 1989, 1990; Simon
et al., 1991). In addition to the loss of responsiveness to
hapten sensitization through UV-irradiated skin, specific
immune tolerance develops when UV-irradiated hosts are
re-challenged through non-irradiated skin (Elmets et al.,
1983). This non-responsiveness is adoptively transferable,
and is a result of the development of CD4þCD25þ
T-regulatory cells, which downregulate effector T-cell re-
sponses either by cell–cell contact or the elaboration of
immunosuppressive cytokines (Schwarz et al., 2004). Most of
these data are the result of studies in animal model systems.
However, these findings are relevant to UV immunosuppres-
sion in humans. It has been demonstrated that humans also
develop hapten-specific tolerance when sensitized with
experimental haptens through UV-irradiated skin (Cooper
et al., 1992).
Imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-c]quino-
lin-4-amine) is an immune response modifier that is a TLR7
agonist (Gorden et al., 2005). Activation of TLR7 results in
activation of the critical transcription factor, NF-kB, and
cytokine production by TLR7 bearing antigen-presenting cell
(APC). Most notably, the genes encoding the cytokines IL-12,
IFN-a and tumor necrosis factor-a, among others, are rapidly
induced after APC are exposed to imiquimod. These
cytokines play a critical role in the inflammatory process,
and also shape adaptive immune responses, favoring Th1-
lymphocyte development when imiquimod-activated APC
present antigens to T-lymphocytes in vitro or in vivo. Because
of these properties, imiquimod has anti-viral and antitumor
activities in a variety of animal model systems. These
preclinical properties have translated well in the clinical
use of imiquimod, which is utilized to treat external genital
warts, actinic keratosis, and basal cell carcinoma (Villa and
Berman, 2004; Vender and Goldberg, 2005).
Among the families of APCs that are targeted by
imiquimod are dendritic cells, including epidermal LCs. In
vivo, with topical application to mouse skin, imiquimod
induces migration of LCs from the epidermis to the local
lymph node. As well, imiquimod enhances CHS responses
(Suzuki et al., 2000). It has been demonstrated that
imiquimod and its hydroxylated derivative, R848, also induce
maturation of human epidermal LCs, enhanced IL-12
production, and significantly increase IFN-g production by
CD4þ T-lymphocytes during antigen presentation by imi-
quimod-treated LCs compared to control LCs (Burns et al.,
2000). It is thought that these effects of imiquimod on
epidermal LCs are an important mechanism of action by
which imiquimod induces Th1-dominant cellular immune
responses in situ during the treatment of external genital warts
and basal cell carcinoma (Kaisho and Akira, 2003).
Previously, it has been reported that IL-12 protects mice
from UV-induced loss of CHS responses (Schmitt et al., 1995;
Schwarz et al., 1996; Schwarz et al., 1998). Because of the
adjuvant effects that imiquimod induces after topical
application to rodent or human skin, and because of its
direct effects on epidermal LCs, including the production of
IL-12, we hypothesized that imiquimod, when applied
topically to mouse skin, may exhibit protective effects against
the acute effects of UV. Herein, we report that topical
applications of imiquimod to mouse skin before UVB
exposures prevent the loss of CHS, hapten-specific tolerance,
and loss of the hapten-specific antibody response. In vitro
studies of XS52, a LC-like cell line indicated that imiquimod
initiates UV-resistant maturation, and that imiquimod and
UVB synergize to enhance IL-12 production by XS52, and
migratory LCs in vivo, preserving CHS. These data suggest
that topical imiquimod treatment may play a role in
preventing UV-induced immunosuppression. Thus, it is
possible that this agent may play a role in preventing skin
cancer development as well as treating fully developed skin
cancers.
RESULTS
To test our hypothesis that local application of the TLR7
agonist, imiquimod can prevent the induction of UV-light
suppression of CHS, mice were first treated with imiquimod,
vehicle, or no treatments before UV irradiation, then
sensitized with 0.5% 2,4 dinitro-1-fluorobenzene (DNFB)
using standard methods (Gaspari and Katz, 1990; Glass et al.,
1990). Consistent with previous reports, mice UV-irradiated
before DNFB sensitization exhibited impaired ear swelling
after challenge with DNFB when compared to non-irradiated
control mice (Figure 1a). Similarly, vehicle treated, UV-
irradiated mice also exhibited impaired CHS. Mice that were
pretreated with imiquimod 5% cream before UV irradiation
and subsequent DNFB sensitization exhibited ear swelling
responses similar to that of non-irradiated, control mice
(Figure 1a). Histologic sections of the ear pinna of mice taken
24 hours after hapten challenge confirmed that imiquimod-
treated UV-irradiated, DNFB-sensitized mice exhibited the
same robust histologic changes as DNFB-sensitized mice,
which was comprised of a dense mononuclear infiltrate,
vasodilation, dermal edema, and spongiosis of the epidermis.
In contrast, vehicle-treated UV-irradiated, DNFB-sensitized
mice, or UV-irradiated, DNFB-sensitized mice exhibited
histologic changes that were similar to naı¨ve mice after
DNFB challenge on the ear pinna (Figure 1b). Topical
imiquimod, when applied 24 hours before sensitization, has
been demonstrated to enhance CHS (Suzuki et al., 2000). We
asked the question if our regimen of two consecutive doses of
imiquimod, followed by a 4-day untreated interval before
sensitization, would have similar effects. As depicted (Figure
1c), this treatment slightly enhanced CHS, but this enhance-
ment was not statistically significant compared to untreated
or vehicle-treated mice.
We tested the role of IL-12 in preventing the impairment of
CHS induced by UV-light exposure. Groups of experimental
mice were treated with an anti-IL-12 monoclonal antibody or
a control monoclonal IgG during imiquimod treatments
before UV-light exposure, and subsequent DNFB sensitiza-
tion. Anti-IL-12, but not control IgG blocked the ability of
imiquimod to prevent the loss of DNFB sensitization induced
by UV-light exposure (Figure 1d). Because topical imiquimod
prevented the loss of responsiveness to hapten sensitization
after UV exposures, we studied epidermal LCs density using
822 Journal of Investigative Dermatology (2006), Volume 126
TH Thatcher et al.
Imiquimod Prevents UV Immunosuppression
indirect immunofluorescence by staining epidermal sheets
with a monoclonal antibody specific for class II major
histocompatibility antigens, a well-characterized LCs marker.
LCs were counted using digital image analysis. Epidermal LC
densities were studied after no treatments, two treatments
with topical vehicle or imiquimod in the absence or presence
of UV-light exposures. LC densities were studied at the time
that hapten sensitization would occur. In the absence of UV
light, neither vehicle nor imiquimod topical treatments
affected LCs density (Figure 2a and b). In the presence of
UV light, neither vehicle nor imiquimod protected LCs from
being depleted. Thus, imiquimod does not protect LCs
depletion after exposure to UV light under these conditions.
Untreated and vehicle treated, UV-irradiated mice were
tolerant to DNFB sensitization (Figure 3a). In contrast, non-
UV irradiated mice and imiquimod treated, UV-irradiated
mice were responsive to a second DNFB sensitization. These
data indicate topical imiquimod treatments before UV
irradiation prevent the induction of immunological tolerance
to hapten sensitization.
Because anti-hapten antibody response after topical
sensitization is dependent upon T-lymphocyte-derived help
in the form of cytokines to drive isotype switching and the
maturation of the humoral immune response (Thomson et al.,
1993), we reasoned that assay of this aspect of the immune
response is a robust, downstream measure of epidermal
antigen presentation by skin-derived LCs. Therefore, 21 days
after the initial hapten sensitization, sera were obtained from
all groups of mice to study for the presence of dinitrophenyl
(DNP)-specific IgG1 and IgG2a using a specific ELISA.
Whereas naı¨ve mice and UV-irradiated, hapten-sensitized
(tolerant) and vehicle-treated, UV-irradiated (tolerant) mice
did not produce detectable DNP-specific IgG2a in their sera,
non-irradiated, DNFB-sensitized and imiquimod-treated, UV-
irradiated, hapten-sensitized mice produced high levels of
DNP-specific IgG2a (Figure 3b). The dilution curves for these
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Figure 1. Topical imiquimod, when applied to mouse skin before UV irradiation, prevents loss of CHS. (a) Groups of mice (N¼ 5/group) were treated with
topical imiquimod cream, its vehicle on abdominal skin for 2 days or nothing before four consecutive doses of UV light (see Figure 7). They were subsequently
sensitized at the UV irradiation site, and challenged on the ear pinna 4 days later; 24 hours later, ear swelling was measured (*Po0.05 compared to non-
irradiated, DNFB-sensitized mice). Data represent mean7SD of ear swelling responses from a single representative experiment that was repeated three times.
(b) Histologic sections were taken from representative mice at 24 hours after hapten challenge, stained with hematoxylin and eosin, and photomicrographs were
taken (original magnification  20 for all sections). (c) Two doses of topical imiquimod, followed by a 4-day untreated interval before sensitization, does not
significantly augment CHS. (d) Administration of anti-IL-12 monoclonal antibody blocks the protective effects of imiquimod on UV immunosuppression
(*Po0.05 compared to the non-sensitized control mice or the imiquimod-treated UV-irradiated mice).
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two latter groups were not significantly different, indicating
the imiquimod treatment maintained full immunologic
responsiveness for antibody production, even in the presence
of UV light. In the absence of UVB exposures, sera from mice
treated with imiquimod before sensitization with DNFB were
not significantly greater than mice sensitized in the absence
of imiquimod (data not shown).
Similarly, for the IgG1-DNP-specific antibody response,
UV-irradiated, hapten-sensitized mice produced a low level
of antibody that was similar to that of vehicle-treated, UV-
irradiated, hapten-sensitized mice. In contrast, non-irra-
diated, hapten-sensitized mice produced significantly greater
levels of hapten-specific antibody, which was identical to
that of imiquimod-treated, UV-irradiated, hapten-sensitized
mice (Figure 3c). These data are consistent with the findings
for the IgG2a hapten-specific response (Figure 3b).
In order to define the mechanisms of the preservation of
hapten sensitization and the prevention of tolerance induc-
tion by topical applications of imiquimod before UV
exposure and subsequent hapten sensitization, an in vitro
model system was used to study the interactions of TLR7
stimulation and UV on epidermal LCs. XS52 is an LC-like cell
line that has been adapted to tissue culture, is growth factor
dependent, and can be maintained in an immature state, but
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Figure 2. Topical imiquimod treatments does not protect epidermal LC from
UV-induced depletion. (a) Mice (N¼ 5/group) were treated as described in
Figure 7, but were not sensitized with DNFB. On day 0 (time of sensitization),
the abdominal skin was taken, and stained with anti-class II MHC monoclonal
antibodies and a fluoresceinated secondary antibody. (b) Digital image
analysis of epidermal LC frequencies (LC numbers/high powered field at
original magnification  400) in the epidermis of mice (*Po0.05 compared
to normal control mice). Data represent mean7SD of LC counts, from a single
representative experiment, that was repeated three times.
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Figure 3. Topical imiquimod treatments prevents UV-light-induced
tolerance to hapten sensitization. (a) Mice (N¼ 5/group) were treated as
in Figure 7. Instead of elicitation on the ear, the groups of mice were
re-sensitized with 20 ml of DNFB 0.5% on shaved, non-irradiated back skin.
Four days later, the animals were challenged on the pinna of the ear with
0.2% DNFB, and ear swelling was measured 1 day later (*Po0.05 compared
to the UV-irradiated, or vehicle-treated, UV-irradiated mice). Baseline (before
the experiment began), and 3 weeks after the first sensitization, blood was
collected from the groups of mice by tail vein bleeding. Hapten-specific
(b) IgG2a and (c) IgG1 were assayed using a specific ELISA (see Materials and
Methods) (*Po0.05 compared to naı¨ve sera, or sera from UV-irradiated, or
vehicle-treated, UV-irradiated mice). Data in ELISA represent the mean7SEM
for the OD of sera from each of the five animals in each group. The data are
from a single representative experiment that was repeated three times.
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has the ability to mature after exposure to a variety of stimuli
(Kitajima et al., 1995). To determine whether XS52 can be
utilized as a model for TLR7 effects, it was necessary to
demonstrate that this cell line expressed transcripts for TLR7.
As demonstrated in Figure 4a, two sets of nested primers to
amplify the 50 or the 30 ends of the cDNA encoding either
TLR7 or TLR8 (labeled as TLR7 #1 or TLR8 #1, or TLR7 #2 or
TLR8 #2, respectively) were utilized to identify TLR7 or TLR8
transcripts, respectively. XS52 (labeled XS52þRT) expressed
transcripts for TLR7 and TLR8. As a control, RNA in the
absence of reverse transcription was subjected to PCR
amplification (labeled XS-RT), and specific PCR amplification
products were not identified (Figure 4a). To confirm that XS52
responded to TLR7 activation by initiating the characterized
biochemical MyD88 signaling pathways (Zhang and Ghosh,
2000), steady-state cytoplasmic IkB was studied (using
Western blotting). Within 15 minutes after exposure to 5 mg/
ml of imiquimod or 50 ng/ml of lipopolysaccharide (LPS), IkB
rapidly decreased from cytoplasmic lysates studied by
Western blotting when treated with imiquimod or LPS (Figure
4b). c-Jun N-terminal kinase (JNK) is known to be rapidly
phosphorylated after TLR stimulation by the MyD88-depen-
dent pathways (Ozato et al., 2002). As expected, XS52
rapidly phosphorylated JNK after exposure to imiquimod or
LPS (Figure 4c). Finally, XS52 also secreted both IL-12p70
and tumor necrosis factor-a 24 hours after exposure to
imiquimod 5 mg/ml or the TLR4 agonist, LPS, 50 ng/ml, which
is a late event that occurs after activation of TLR7 or TLR4
(Figure 4d).
Having demonstrated that XS52 expresses TLR7 tran-
scripts, activates the appropriate biochemical signaling path-
ways after exposure to imiquimod, leading to cytokine
secretion, the interactions of TLR7 and UV-light exposures
were then examined. XS52 was exposed to 5 mg/ml imiqui-
mod, 5 or 25 mJ/cm2 of UVB or 5 mg/ml imiquimod for
4 hours, followed by 5 or 25 mJ/cm2 of UVB. XS52 produce
low levels of IL-12p70 (specific ELISA) in the absence of
imiquimod (Figure 5a). Similarly, UV exposures did not result
in any increase in IL-12p70 above that of control XS52. As
expected, 5 mg/ml of imiquimod increased IL-12p70 secre-
tion. When XS52 was stimulated with imiquimod for 4 hours,
followed by UV exposure, low doses of UVB did not interfere
with XS52 IL-12p70 secretion. At the higher dose of UVB,
there was a significant augmentation of IL-12p70 secretion
compared to XS52 stimulated with imiquimod alone.
A functional assay was used to study the interaction of
TLR7 activation with UVB exposures. In this experiment,
XS52 was exposed to 5 or 10 mg/ml of imiquimod, for
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Figure 4. XS52, an LC-like mouse cell line, expresses TLR7 and TLR8 transcripts, activates biochemical signaling pathways, and secretes cytokine after
exposure to imiquimod in vitro. (a) XS52 cells express transcripts for TLR7 and TLR8 (þ indicates reverse transcription;  indicates absence of reverse
transcription) (b) Nuclear-free lysates from XS52 stimulated with medium alone, or imiquimod or LPS downregulate IkB as demonstrated by Western blotting.
(c) XS52 stimulated with LPS (þ L) or imiquimod (þ I) rapidly phosphorylate JNK as demonstrated by Western blotting. (d) Imiquimod or LPS rapidly induce
tumor necrosis factor-a and IL-12p70 secretion by XS52 over a 24-hour period. Data represent mean7SD for data depicted in the ELISA (*Po0.05 compared to
control (unstimulated) XS52; **Po0.001 compared to control (unstimulated) XS52; analysis of variance).
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24 hours, or exposed to these doses of imiquimod for 4 hours,
washed thoroughly to remove this agent, and then irradiated
with 10 mJ/cm2 of UVB. Then, the treated XS52 were studied
for their ability to trigger IFN-g secretion in an allogeneic
mixed lymphocyte reaction (H-2b CD4þ T-lymphocytes)
(Steinman and Inaba, 1985-30). T-lymphocytes cultured in
medium alone produced low levels of IFN-g, whereas XS52
induced robust IFN-g secretion into culture supernatants
(Figure 5b). XS52 irradiated with UVB (10 mJ/cm2) triggered
an impaired IFN-g secretion by allogeneic T-lymphocytes.
Neither 5 nor 10 mg/ml of imiquimod-treated XS52 augmen-
ted IFN-g secretion by allogeneic T-lymphocytes. When XS52
was treated with 5 or 10 mg/ml of imiquimod, followed by
10 mJ/cm2 of UVB, there was an augmented IFN-g response,
which was significantly greater than that triggered by UVB-
treated XS52 or imiquimod-treated XS52.
To determine whether the synergy between TLR7 activa-
tion and UVB exposure in augmenting cytokine secretion by
XS52 was relevant to the in vivo model system, another in
vivo experiment that focused on cellular events in local
lymph node tissues was then completed. Groups of animals
were treated on abdominal skin with vehicle alone,
imiquimod alone, UVB alone, or imiquimod and UVB, and
local lymph nodes in the inguinal area were dissected,
followed by enrichment of CD11cþ dendritic APCs. These
enriched APCs were then cultured in medium alone, or
medium containing two concentrations of LPS (10 or 50mg/
ml). IL-12p70 secretion was studied using a specific ELISA
(Figure 6). APCs cultured in medium alone did not produce
detectable IL-12p70 (data not shown). Whereas APCs from
vehicle-treated animals produced low, but detectable IL-
12p70 in response to LPS, there was significant augmentation
of the IL-12p70 response in APCs from imiquimod-treated
mice. APCs from vehicle/UV-irradiated animals exhibited an
impaired IL-12p70 response, which was less than the vehicle
alone treated animals, or the imiquimod-treated animals.
There was a marked augmentation of the IL-12p70 secretion
by the APCss from the imiquimod/UV-treated animals. These
data indicate that the synergy between TLR7 activation and
UV exposures in augmenting IL-12p70 secretion by XS52 was
indeed relevant to the mechanism of imiquimod in the in vivo
model system in which there TLR7 activation in vivo renders
mice resistant to the deleterious effects of UVB.
DISCUSSION
Application of topical imiquimod to mouse skin prevented
the loss of CHS induced by UV, as measured by ear swelling
responses, and analysis of histologic specimens of hapten
challenge sites in mice (Figure 1a and b). The role of IL-12 in
the mechanism of action of imiquimod on UV immunosup-
pression was confirmed by the administration of a specific
anti-IL-12 monoclonal antibody, which blocked the protec-
tive effects of topical imiquimod (Figure 1c). These data are
consistent with the observation that the administration of
recombinant IL-12 prevents UV suppression of CHS, and
overcomes UV-induced tolerance (Schwarz et al., 1996).
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Figure 6. Topical applications of imiquimod followed by UVB exposures
significantly enhances IL-12p70 secretion by local lymph node CD11cþ
dendritic APC populations. Mice (N¼5/group) were treated in vivo with
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Data are derived from a single, representative experiment that was repeated
three times.
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However, Schwarz et al. (1996) utilized a recombinant
cytokine to protect mice from UV-immunosuppression by
systemic (intraperitoneal) injections. The current study
utilized a TLR7 agonist, which was administered topically,
and is a known IL-12 inducer. Both studies demonstrate the
critical role of IL-12 in preserving CHS in the setting of UV-
light irradiation. Additionally, topical applications of imiqui-
mod before UV exposure also prevented the induction
immune tolerance, further demonstrating the similarities
between the two methods of modulating UV-light damage
to the skin immune system.
The frequency of epidermal LCs is an important factor in
determining whether sensitization or tolerance occurs after
hapten application (Toews et al., 1980; Aberer et al., 1981).
UV light is thought to impair CHS and induce immune
tolerance because it depletes epidermal LCs (Cruz et al.,
1989, 1990; Simon et al., 1991). This depletion is thought to
be the result of UV-light-induced migration (Kolgen et al.,
2002), whereby the UV-impaired LCs in local lymph nodes
result in the formation of T-regulatory cells that suppress
CHS, and are adoptively transferable to naı¨ve mice (Schwarz
et al., 2004). Studies of the protective effects of IL-12 on UV
immunosuppression demonstrated that injections of this
cytokine immediately before UV exposures prevented LCs
depletion from the epidermis (Schwarz et al., 2005). Topical
imiquimod therapy has been demonstrated to induce migra-
tion of epidermal LCs from the skin to local lymph nodes
within 24 hours of application (Suzuki et al., 2000). Thus, the
combination of topical imiquimod followed by UV irradia-
tion presented the potential for exaggerated migration (ie,
depletion) from the epidermis before sensitization with
hapten. It is noteworthy that the regimen of topical
imiquimod exposures in the current studies did not affect
LCs, which is in contrast to previous studies of LCs migration
that used a different treatment regimen (Suzuki et al., 2000).
Because topical imiquimod prevented loss of CHS
(Figure 1) and tolerance induction (Figure 3a), epidermal LC
densities were studied. In contrast to the data derived from
the studies of recombinant IL-12, topical applications of
imiquimod did not prevent UV-induced depletion of epider-
mal LCs (Figure 2). It is noteworthy that the studies with the
IL-12 involved exposure to UV light first, then administration
of IL-12 injection immediately before DNFB sensitization.
Our protocol involved two daily doses of imiquimod, then
four daily doses of UVB at 70 mJ/cm2. In our study, DNFB
hapten was not applied to mouse skin before immunochem-
istry to study LC densities. Thus, differences in experimental
methods may have resulted in differing outcomes regarding
LC densities in response to UV depletion.
The rationale for studying hapten-specific antibody
responses are related to observations that epicutaneously
hapten-sensitized mice produce antibodies specific for the
allergens, which is the result of T-cell-derived help in the
form of cytokines that occur in germinal centers as a result of
antigen presentation and polarized cytokine production.
Study of hapten-specific IgG2a production (an antibody
response that is driven by Th1-derived cytokines such as
IFN-g) (Jurado et al., 1989) indicated that UV irradiation
rendered DNFB-sensitized mice totally unresponsive to DNP,
with antibody production similar to naı¨ve mice, or mice
treated with vehicle before DNFB sensitization. In contrast,
imiquimod-treated, UV-irradiated mice responded as vigor-
ously as did non-irradiated, DNFB-sensitized mice, indicat-
ing that topical imiquimod preserved Th1-lymphocyte help to
drive cytokine production. Study of hapten-specific IgG1
production (an antibody response that is driven by Th2-
derived cytokine such as IL-4) (Coffman et al., 1989)
indicated that UV irradiation rendered these mice DNP
hyporesponsive, with an antibody responsive significantly
greater than that of naı¨ve mice. Imiquimod treatment before
UV irradiation also reversed the hyporesponsiveness, render-
ing this group’s antibody response the same as non-irradiated,
DNFB-sensitized mice. Collectively, these data suggest that
UV irradiation before hapten sensitization impairs antigen
presentation, and subsequent T-lymphocyte help for hapten-
specific antibody production, and that treatment of mouse
skin with topical imiquimod prevents this impairment.
XS52 is derived from the epidermis from neonatal mouse
skin, is growth factor-dependent, and is maintained in an
immature state, but responds to maturational stimuli (Kitajima
et al., 1995). We demonstrate that XS52 cells express mRNA
encoding TLR7 and TLR8. After exposure to imiquimod, XS52
cells degrade IkB (an event associated with NF-kB transport
to the nucleus), phosphorylate JNK, and secrete IL-12p70 and
tumor necrosis factor-a (Figure 4a–e). These represent the
molecular events associated with TLR signaling by the
MyD88-dependent pathway (Zhang and Ghosh, 2000). Thus,
XS52 cell line is representative of an imiquimod responsive
cell type, such as epidermal LCs (Burns et al., 2000; Suzuki
et al., 2000). Direct studies of the effects of TLR7 activation
before UV irradiation demonstrate that even brief pulse
incubations of XS52 with imiquimod (4 hours before UV-
irradiation) render this cell type able to secrete IL-12p70.
Because the combination of imiquimod before UV irradiation
results in a greater production of IL-12p70 than either alone,
this suggests that TLR7 and UV irradiation are synergistic in
enhancing the production of this critical cytokine (Figure 5a).
Because Th1-lymphocytes play a critical role in CHS
(Hauser, 1990) and UV irradiation has been demonstrated to
result in impaired antigen presentation specifically to Th1-
lymphocytes (Simon et al., 1991), the ability of imiquimod to
preserve Th1-cytokines in the setting of UV irradiation was
studied using an allogeneic mixed lymphocyte reaction
(MLR) as a measure of antigen presentation (Figure 5b).
Whereas UV-irradiated XS52 triggered impaired IFN-g
production by CD4þ T-lymphocytes, imiquimod treatment
of XS52 before UV irradiation significantly enhanced IFN-g
production by CD4þ T-lymphocytes. This IFN-g production
was greater than that stimulated by UV-irradiated XS52 or
imiquimod-treated XS52. XS52, cultured in medium alone or
in the presence of imiquimod, did not produce IFN-g (data
not shown). These data again suggest that imiquimod and UV
irradiation synergize to enhance IFN-g production, which is a
known effect of IL-12 (Langrish et al., 2004). The lack
inability of imiquimod by itself to act on XS52 to enhance
IFN-g triggering in T-lymphocytes (compared to control XS52)
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is in contrast to previous studies of human epidermal LCs in
which imiquimod enhances the ability of the cells to trigger
IFN-g in T-lymphocytes (Burns et al., 2000). It is possible that
higher doses of imiquimod may be necessary in this cell line.
Our ex vivo studies of IL-12p70 production by lymph node
APCs demonstrated that such CD11cþ APC from UV-
irradiated animals were indeed deficient in their ability to
produce IL-12p70 after stimulation with LPS when compared
to non-irradiated mice, or imiquimod-treated mice (Figure
5b). Consistent with our in vitro studies of the interactions of
TLR7 activation and UV irradiation on XS52, there was a
synergy between imiquimod treatment and UV irradiation in
the enhancement of IL-12p70 secretion when compared to
lymph node APCs from imiquimod alone treated mice or UV-
irradiated mice. Thus, these data consistently indicate that
TLR7 activation before exposure to UV irradiation results in
an enhanced secretion of IL-12p70, which is likely to be
responsible for conferring resistance to UV immunosuppres-
sion, and subsequent loss of CHS. One possible explanation
for this synergy between TLR7 and UV irradiation in
triggering enhanced IL-12 secretion is both these stimuli
activate NF-kB to move into the nucleus and activate gene
transcription (Abeyama et al., 2000; Zhang and Ghosh,
2000). This possibility warrants further study.
Given that imiquimod augments LC function (Burns et al.,
2000) and CHS (Suzuki et al., 2000), it is possible that all of
the observations related to its effects on UV on the skin
immune system can be explained by the ability of imiquimod
to enhance LC function (ie, adjuvant activities), and hence
CHS, rather than a true prevention of UV immunosuppres-
sion.
Recombinant IL-12 renders mice resistant to UV immu-
nosuppression because it triggers DNA repair of UV-induced
cyclobutane pyrimidine dimers (Schwarz et al., 2005), which
are known to be a critical lesion in migratory APCs, resulting
in immune defects after UV exposure (Kripke et al., 1992).
This raises the possibility that imiquimod, by stimulating IL-
12 p70 gene expression, may stimulate DNA repair in APCs
and other epidermal cells. This would present a novel
function for TLR signaling, mediated directly by TLR signaling
itself, or indirectly by induced cytokines such as IL-12.
These results suggest that there may be a new paradigm for
the prevention of photoimmunosuppression using topical
agents. Previous studies have suggested that topical sunsc-
reens (Whitmore and Morison, 1995), and possibly topical
DNA repair enzymes (Yarosh and Klein, 1996), can dampen
photoimmunosuppression. Topical imiquimod and its deri-
vatives may present an opportunity to prevent photoimmu-
nosuppression by manipulating dendritic cell responses to
UV light by stimulating TLR signaling. This possibility
warrants further study, and suggests that imiquimod may
play a role in the prevention of skin cancer development in
the setting of chronic UV-light exposures.
MATERIALS AND METHODS
Experimental mice
C57BL/6 female mice, 8 weeks old were purchased from Jackson
Laboratories (Bar Harbor, ME). These animals were chosen because
they have been demonstrated to exhibit a phenotype of susceptibility
to UV-induced suppression of CHS (Toews et al., 1980; Elmets et al.,
1983). Animals were kept in standard housing conditions, fed mouse
chow ad libatum, and exposed to a 12 hours light/dark cycle. All
experimental procedures were reviewed and approved by the
University of Maryland Institutional Animal Care and Use Commit-
tee.
Chemicals
Imiquimod (R-837) 5% cream and its vehicle cream were used for
topical applications, and were provided by 3M Pharmaceuticals (St
Paul, MN). For the in vitro studies, imiquimod powder was used
(also provided by 3M Pharmaceuticals). It was prepared as a stock
solution in sterile water at 1 mg/ml, and diluted to the appropriate
working concentration in complete medium
Immunofluorescence staining
Abdominal skin samples were scraped of subcutaneous fat,
incubated with ammonium thiocyanate, washed with phosphate-
buffered saline, and fixed in acetone. The epidermal sheets were
stained overnight for LCs with an anti I-A/I-E monoclonal antibody
(M5.114, hybridoma from American Type Culture Collection), then
incubated with a fluorescein conjugated secondary anti-rat antibody
(IgG) and examined using an epifluorescence microscope (Nikon
E600) equipped with a digital spot camera. A monoclonal rat IgG of
irrelevant specificity was used as an isotype control for staining.
Digital image analysis was used to count epidermal LCs density
on abdominal skin after topical imiquimod or vehicle or no
treatments before UV exposure. Image Pro Plus Version 4.5 for
Windows (Media Cybernetics, Silver Spring, MD) software program
was used to count stained epidermal LCs.
Hapten sensitization
For hapten sensitization, the experimental allergen DNFB (Eastman
Chemicals, Kingsport, TN) was utilized. To sensitize mice, 0.5%
DNFB in 4:1 acetone/olive oil in a 20ml volume was pipetted onto
shaved abdominal skin on days 0 and þ 1; to elicit CHS, the allergic
mice (or naı¨ve mice as a negative control) were challenged with
0.2% DNFB in acetone/olive oil in a 20 ml volume (half of the total
volume to each side of the ear). Ear swelling was measured on the
right ear 24 hours after challenge using an engineer’s thickness gauge
caliper (Mitutoyo, Cole-Parmer Instrument company, Tylertown,
MS). Change in ear thickness was calculated by subtracting the
baseline ear thickness to that measured 24 hours after hapten
challenge (Gaspari and Katz, 1990). Additionally, skin biopsy
specimens were taken from the pinna of the ear in selected animals
at 24 hours after hapten challenge to study the histologic changes.
The specimens were paraffin-embedded, sectioned onto glass slides,
stained with hematoxylin–eosin, and examined and photographed
using a E600 Nikon microscope equipped with a Spot Digital
camera (Diagnostic Instruments, Inc., Sterling Heights, MI) in the
brightfield mode.
To block the biologic effects of IL-12 during topical imiquimod
treatments before UV irradiation, rat anti-mouse IL-12 p70 (C15.6,
Biosource, Camarillo, CA) or rat IgG1 (isotype control) (BD
Pharmingen, San Diego, CA), anti-IL-12 or the isotype control
antibody was administered by intraperitoneal injections (150 mg/
injection) daily during the 2 days of imiquimod treatments.
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For all of these in vivo experiments, there were five mice in each
experimental group. The depicted data represent the mean7SD for
each experimental group. Every in vivo experiment was repeated
three times to assure reproducibility.
UV light source
Groups of mice were irradiated with a panel of 48’’ Q-Sun light bank
(Q-Panel Laboratory products, Cleveland, OH) (equipped with a
UVC WG320 filter) at a distance of 12 inches from the light source to
their shaved abdominal skin. The spectral emission profile of this
light source closely mimics that of natural sunlight, emitting
predominantly UVA. A UVB radiometer (National Biologic Corpora-
tion, Twinsburg, OH) was used to determine UVB output, and
calculate the time necessary to deliver the desired doses of UVB.
Mice received four daily doses of 70 mJ/cm2 of UVB, a schedule of
UV radiation that has been demonstrated to inhibit the afferent phase
of CHS (Glass et al., 1990).
The protocol for studying the prevention of UV-induced loss of
CHS is summarized in Figure 7. Briefly, groups of mice (N¼ 5/group)
were treated with topical 5% imiquimod cream (0.1 ml dispensed
from a tuberculin syringe) or a similar volume of vehicle or nothing
on shaved abdominal skin for 2 consecutive days before the four
consecutive daily doses of UV radiation. Animals were fitted with
soft collars to prevent the ingestion of the topical applications as a
result of their grooming activities. On the day of the last dose of the
UV radiation and the following day, all experimental groups were
sensitized with 0.5% DNFB (on Day 0 and þ 1). The first sensitizing
dose of DNFB was applied 4 hours after the final dose of UV
radiation.
To study the prevention of UV-induced tolerance to hapten
sensitization, this protocol was used with minor modifications. All
animals received the topical treatments, UV exposures and initial
sensitization through UV-irradiated abdominal skin as outlined in
Figure 7. Instead of eliciting on the ear pinna on day þ 4, animals
received a second sensitization with 0.5% DNFB on shaved, non-
UV-irradiated dorsal skin of the back (days þ 7 and þ 8). Four days
later (day þ 11), the mice were challenged on the ear pinna with
0.2% DNFB, and the following day (day þ 12), ear swelling was
measured.
ELISA to detect hapten-specific antibody responses
ELISA plates were coated for 8 hours with DNP-conjugated
ovalbumin at a concentration of 10 mg/ml. Blocking solution (1%
bovine serum albumin and 0.05% Tween) was then added for
2 hours. The wells were then washed with phosphate-buffered saline
0.05% Tween. The test sera were added for 8 hours at 41C. The wells
were washed, and then biotinylated goat anti-mouse IgG1 (BD
Pharmingen) (1:8,000 dilution) or biotinylated goat anti-mouse
IgG2a (BD Pharmingen) (1:6,000) was added for 2 hours, followed
by streptavidin-conjugated horse radish peroxidase for 45 minutes.
Color substrate was added, color was allowed to develop, and then
stopped by adding 2 N H2SO4. The plates were read at 450 nm in a
Benchmark Biorad ELISA plate reader.
ELISA to detect secreted cytokines
Commercially available ELISA (BD OptEIA) were used to detect
secreted cytokines into cell-free culture supernatants. For IL-12p70
and tumor necrosis factor-a, supernatants were collected over a 24-
hours period. The limit of detection for these ELISAs was 10 ng/ml for
the cytokines of interest. For IFN-g, culture supernatants were
collected after 72 hours of the mixed lymphocyte reaction.
Mixed lymphocyte reaction
For the MLR, XS52 (H-2d) (a generous gift from Dr Akira Takashima,
UTSW) were utilized as the stimulator APC, at 20,000 cells/well of a
round-bottomed 96-well plate. As responder T-cells, the spleen was
removed from a C57BL/6 mouse (H-2b), passed through a nylon
wool column to deplete accessory cells, counted, and then added to
a 96-well microtiter plate at 200,000 T cells/well in RPMI 1640 with
10% fetal calf serum, glutamine, and antibiotics. The cells were
incubated in a 5% CO2 atmosphere at 371C for 72 hours before
collecting supernatants, which were frozen at 201C until cytokine
ELISA were performed.
To treat XS52 before the MLR, this cell line was cultured in
complete medium without growth factors for 24 hours before adding
imiquimod at 5–10 mg/ml for 4 hours. The culture medium containing
imiquimod was removed, and the cells were rinsed with phosphate-
buffered saline before UV irradiation with the Q-panel light source
(see above). A UVB radiometer was used to measure UVB doses.
These doses were 5–25 mJ/cm2, and have been demonstrated to
induce NF-kB signaling in the XS cell line in the absence of cell
death (Abeyama et al., 2000). After the UV radiation, the XS52 were
cultured in complete medium without growth factors, then harvested
for MLR 20 hours after UVB exposure. Thus, with both the
imiquimod and UVB treatments, a total of 24 hours elapsed before
the XS52 were added to the MLR. This experiment was repeated
three times to assure reproducibility.
Enrichment of dendritic APCs from local lymph nodes
Regional lymph nodes were dissected from the inguinal area of mice
treated on abdominal skin with vehicle alone, vehicle and UV
irradiation, imiquimod alone, or imiquimod treatment before the UV
exposures (N¼ 5 mice/group) as summarized in Figure 7. The lymph
nodes from each experimental group were pooled together, then
mechanically disrupted into a single-cell suspension, and pipetted
onto a density gradient as previously described (Gorman et al.,
2005). The cells at the interface were collected, washed, counted,
and then incubated with anti-CD11c (BD Biosciences, San Diego,
Imiquimod
or vehicle
or nothing
daily × 2
days on
abdomen
UVB 70 mJ/cm2 on abdomen
daily × 4 days
Elicit on
pinna of
ear with
0.2%
DNFB
Measure
ear swelling
Sensitize with 0.5% DNFB,
20  l on abdomen × 2 days
−5 −4 −3 −2 −1 0 +1 +2 +3 +4 +5
Figure 7. Protocol for studying the prevention of UV suppression of CHS
with topical applications of imiquimod or its vehicle. Groups (N¼5/group)
of mice were treated with imiquimod 5% cream, its vehicle alone, or nothing
for two consecutive days before four daily doses of UV light before
sensitization with 0.5% DNFB. They were subsequently challenged on the ear
pinna with 0.2% DNFB, and then ear swelling was measured. This critical
experiment was repeated three times, and found to be reproducible.
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CA) that had been coupled onto the surface of Tosyl activated
magnetic beads (Dynal Corporation, Oslo, Norway), and then
placed over a magnet. Non-adherent cells were removed. The
adherent cells were released from the magnet, washed, counted, and
used as lymph node dendritic cells. The resulting cells were 490%
M5/114 (class II MHC) positive, and exhibited a dendritic
morphology. These dendritic cells were cultured in medium alone
(50,000 cells/well) or with imiquimod or LPS (a generous gift from Dr
Stephanie Vogel) in a 200ml volume for 24 hours, and supernatants
were collected and studied for IL-12p70 content using a commer-
cially available ELISA.
Western blotting
To study IkB cytoplasmic content in XS52, Western blotting was
used. Before and 15 minutes after stimulation with imiquimod 5 mg/
ml or LPS, 1 106 cells were lysed with lysis buffer (RIPA buffer,
Sigma, St Louis, MO) and then scraped from the culture vessel,
placed on ice and then on a rocking platform for 10 minutes. The
lysate was then centrifuged at 15,000 g for 3 minutes. The
cytosolic fraction (supernatant) was collected. Protein concentration
was determined (Bradford method). The lysate was then run on a
10% Bis-Tris NuPage gel under reducing conditions with MOPS SDS
running buffer. The separated proteins were transferred to a
nitrocellulose membrane, stained with a rabbit polyclonal antiserum
specific for mouse IkB (Santa Cruz #SC-371, Santa Cruz, CA).
Staining was detected using Western Breeze Chemiluminescent
Immunodetection kit (Invitrogen, Carlsbad, CA); a Chemdoc (Biorad,
Hercules, CA) digital imaging system was used to record the
resulting images.
To detect phosphorylation of JNK-1, 2 in XS52 or those cells
stimulated with imiquimod or LPS, 1 106 cells were lysed with
lysis buffer (RIPA buffer with a phosphatase inhibitor cocktail II,
Sigma, St Louis, MO) scraped from the culture vessel. Cellular debris
was pelleted and removed, and protein concentration determined
(Bradford method). The lysate was then run on a 10% Bis-Tris
NuPage gel under reducing conditions with MOPS SDS running
buffer. The separated proteins were transferred to a nitrocellulose
membrane, and stained with a rabbit polyclonal antibody specific
for JNK1, 2. Staining was detected using Western Breeze Chemilu-
minescent Detection kit (Invitrogen); a Chemdoc (Biorad) digital
imaging system was used to record the resulting images.
RNA extraction and cDNA synthesis (RNeasy Mini Protocol,
Qiagen, Valencia, CA)
Cultured cells (from one well of six-well plate) were lysed by adding
350ml of b-mercaptoethanol in buffer RLT (1:100) directly into the
culture vessels. The cell lysate was placed into a microcentrifuge
tube and vortexed to ensure good mixing. The sample was then
homogenized by placing it into a QIAshredder spin column and
centrifuging for 2 minutes at maximum speed. 350 ml of 70% ethanol
in DEPC H2O was added to the homogenized lysate and mixed well.
The 700ml sample was placed in an RNeasy mini column and
centrifuged for 15 seconds at X10,000 r.p.m., and the flow-through
discarded. Seven hundred microliters of Buffer RW1 was added to
the RNeasy column, and centrifuged again for 15 seconds at
X10,000 r.p.m. After transferring the RNeasy column into a new
2 ml collection tube, 500 ml of Buffer RPE was added to the column
and centrifuged for 15 seconds at X10,000 to wash the column.
Another 500 ml of Buffer RPE was added and column centrifuged for
2 minutes at X10,000 r.p.m. to dry the silica-gel membrane. The
column was centrifuged at full speed for 1 minute in order to
eliminate any chance of possible Buffer RPE carryover. The RNA was
eluted with 30 ml of RNAse-free water.
RNA samples (2 mg) were placed in microcentrifuge tubes and
RNAse-free water was added to bring the samples to 8 ml (or 20 ml).
The RNA solution was heated to 651C for 10 minutes, then chilled at
41C for 5 minutes. Five microliters (or 11 ml) of the bulk first-strand
cDNA reaction mix was then added to the heat-denatured RNA
solution, followed by 1ml of DTT solution and 1 ml of pd(N)6 (First-
Strand cDNA Synthesis Kit; Amersham, Piscatway, NJ). The mixture
was pipetted up and down several times to ensure a good mix, and
incubated at 371C for 1 hour. After the incubation, the completed
first-strand reaction product was heated to 901C for 5 minutes to
denature the RNA-cDNA duplex and to inactivate the reverse
transcriptase. It was then cooled at 41C for 5 minutes. In all,
0.5–1.0ml of this final cDNA product was used for PCR amplification.
Reverse transcription-PCR
Detection of TLR7 and TLR8 mRNA was performed using reverse
transcription-PCR according to previously published methods
(Gaspari et al., 1998). The annealing temperature was 551C,
followed by 35 cycles of amplification using a PCR Sprint (Hybaid,
Inc., Waltham, MA). Primers were designed according to published
sequences (AY035889.1 for murine TLR7 and AY035890.1 for
murine TLR8), and spanned one intron.
TLR7 primers (first set, 50 end of gene; amplification product:
167 bp):
50-CCTGTTCTACTGGGGTCCAA-30
30-GCCTCAAGGCTCAGAAGATG-50
TLR7 primers (second set, 30 end of gene; amplification product:
161 bp):
50-GGAGCTCTGTCCTTGAGTGG-30
30-CAAGGCATGTCCTAGGTGGT-30
TLR8 primers (first set, 50 end of gene; amplification product:
195 bp):
50-GGCACAACTCCCTTGTGATT-30
30-CATTTGGGTGCTGTTGTTTG-50
TLR8 primers (second set, 30 end of gene; amplification product:
163 bp):
50-CTTCCAAACTTGGCAACCAT-30
30-GAAGACGATTTCGCCAAGAG-50
After amplification, the samples were loaded on a 4% agarose
gel, stained, and photographed. Omission of reverse transcriptase
controlled for DNA contamination.
Statistical analyses
Graph Pad Instat and Prism software programs (Graph Pad, San
Diego, CA) were used to compare quantitative data from experi-
mental groups for statistical significance. For comparisons between
multiple groups, analysis of variance was used; Po0.05 were
considered to be statistically significant.
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